###begin article-title 0
Wnt/beta-catenin signaling controls development of the blood-brain barrier
###end article-title 0
###begin p 1
###xml 30 51 30 51 <email xmlns:xlink="http://www.w3.org/1999/xlink">stefan.liebner@kgu.de</email>
###xml 66 95 66 95 <email xmlns:xlink="http://www.w3.org/1999/xlink">holger.gerhardt@cancer.org.uk</email>
###xml 111 147 111 147 <email xmlns:xlink="http://www.w3.org/1999/xlink">elisabetta.dejana@ifom-ieo-campus.it</email>
Correspondence to S. Liebner: stefan.liebner@kgu.de; H. Gerhardt: holger.gerhardt@cancer.org.uk; or E. Dejana: elisabetta.dejana@ifom-ieo-campus.it
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 211 214 <span type="species:ncbi:9685">cat</span>
###xml 372 375 <span type="species:ncbi:9685">cat</span>
###xml 442 445 <span type="species:ncbi:9685">cat</span>
###xml 599 602 <span type="species:ncbi:9685">cat</span>
###xml 814 817 <span type="species:ncbi:9685">cat</span>
###xml 907 910 <span type="species:ncbi:9685">cat</span>
The blood-brain barrier (BBB) is confined to the endothelium of brain capillaries and is indispensable for fluid homeostasis and neuronal function. In this study, we show that endothelial Wnt/beta-catenin (beta-cat) signaling regulates induction and maintenance of BBB characteristics during embryonic and postnatal development. Endothelial specific stabilization of beta-cat in vivo enhances barrier maturation, whereas inactivation of beta-cat causes significant down-regulation of claudin3 (Cldn3), up-regulation of plamalemma vesicle-associated protein, and BBB breakdown. Stabilization of beta-cat in primary brain endothelial cells (ECs) in vitro by N-terminal truncation or Wnt3a treatment increases Cldn3 expression, BBB-type tight junction formation, and a BBB characteristic gene signature. Loss of beta-cat or inhibition of its signaling abrogates this effect. Furthermore, stabilization of beta-cat also increased Cldn3 and barrier properties in nonbrain-derived ECs. These findings may open new therapeutic avenues to modulate endothelial barrier function and to limit the devastating effects of BBB breakdown.
###end p 3
###begin p 4
###xml 75 78 <span type="species:ncbi:9685">cat</span>
###xml 189 192 <span type="species:ncbi:9685">cat</span>
###xml 402 407 <span type="species:ncbi:10090">mouse</span>
Abbreviations used in this paper: 4OHT, 4-hydroxy-tamoxifen; BAT-Gal, beta-cat-activated transgene driving expression of nuclear beta-galactosidase reporter; BBB, blood-brain barrier; beta-cat, beta-catenin; Cldn, claudin; CM, conditioned medium; EC, endothelial cell; GOF, gain of function; IF, immunofluorescence; IHC, immunohistochemistry; Lef, lymphoid enhancer factor; LOF, loss of function; MBE, mouse brain microvascular EC; Ocln, occludin; P-face, protoplasmic fracture face; Plako, plakoglobin; Plvap, plamalemma vesicle-associated protein; TAT, transactivating regulatory protein; TCF, T cell factor; TJ, tight junction; VE-cad, vascular endothelial cadherin; ZO-1, zonula occludens 1.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 206 222 206 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Engelhardt, 2003</xref>
###xml 381 405 381 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Furuse and Tsukita, 2006</xref>
###xml 598 618 598 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">Wolburg et al., 2003</xref>
###xml 620 638 620 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Nitta et al., 2003</xref>
Endothelial cells (ECs) of brain capillaries form an active permeability barrier and transport system known as the blood-brain barrier (BBB), which is instrumental in the control of the brain fluid milieu (Engelhardt, 2003). Complex tight junctions (TJs) between brain ECs constituted by proteins of the claudin (Cldn) family and occludin (Ocln) seal off the paracellular pathway (Furuse and Tsukita, 2006). Whereas Cldn5 is also found in nonbarrier endothelium, Cldn3 is predominantly present in brain ECs, where it plays a specific role in the establishment and maintenance of BBB TJ morphology (Wolburg et al., 2003; Nitta et al., 2003).
###end p 6
###begin p 7
###xml 194 210 194 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Engelhardt, 2003</xref>
###xml 621 642 621 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Liebner et al., 2000b</xref>
###xml 644 660 644 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Engelhardt, 2006</xref>
###xml 604 611 <span type="species:ncbi:9606">patient</span>
BBB ECs also express specific transporters for glucose, amino acids, and, to prevent damage to the brain, members of the multidrug resistance transporter family (also known as ABC transporters; Engelhardt, 2003). ECs rapidly lose their barrier and selective transport properties under pathological conditions in vivo (ischemia and tumor) and upon cultivation in vitro, indicating that the healthy brain provides inductive and maintenance signals for the BBB. Our limited knowledge of the nature of these signals and of the molecular regulation of the BBB hampers the development of BBB model systems and patient therapy (Liebner et al., 2000b; Engelhardt, 2006).
###end p 7
###begin p 8
###xml 332 342 323 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Moon, 2005</xref>
###xml 113 116 <span type="species:ncbi:9685">cat</span>
###xml 167 170 <span type="species:ncbi:9685">cat</span>
###xml 384 387 <span type="species:ncbi:9685">cat</span>
A major pathway regulating brain development is the canonical Wnt/wingless pathway acting via beta-catenin (beta-cat) stabilization. This favors translocation of beta-cat to the nucleus, where it binds to transcription factors of the lymphoid enhancer factor (Lef)/T cell factor (TCF) family, and thus modulates gene transcription (Moon, 2005). In this study, we report that Wnt/beta-cat signaling in brain ECs in vitro and in vivo during brain angiogenesis and postnatal vascular maturation is necessary to induce barrier properties in brain ECs.
###end p 8
###begin title 9
Results and discussion
###end title 9
###begin title 10
###xml 24 27 <span type="species:ncbi:9685">cat</span>
Active endothelial beta-cat signaling correlates with central nervous system vascularization, BBB development, and maturation
###end title 10
###begin p 11
###xml 272 289 263 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A, a and b</xref>
###xml 392 409 383 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B, a and b</xref>
###xml 492 517 483 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B [c and d] and C</xref>
###xml 606 627 597 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B [e&#8211;h] and C</xref>
###xml 800 808 791 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 8 11 <span type="species:ncbi:9685">cat</span>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 118 121 <span type="species:ncbi:9685">cat</span>
In beta-cat-activated transgene driving expression of nuclear beta-galactosidase reporter (BAT-Gal) mice for Wnt/beta-cat signaling, we observed strong LacZ-reporter activity in ECs starting at embryonic day (E) 9.5 when the perineural vascular plexus is fully developed (Fig. 1 A, a and b). Throughout brain angiogenesis up to E15.5, numerous ECs in the immature network were LacZ positive (Fig. 1 B, a and b). From E15.5 to 17.5, the number of LacZ-positive nuclei decreased significantly (Fig. 1, B [c and d] and C) to a level that was maintained during early postnatal stages in vessels of the cortex (Fig. 1, B [e-h] and C). Adult brain vessels rarely displayed LacZ-positive nuclei, suggesting that Wnt signaling activity is required for BBB maturation but is low when the BBB is fully mature (Fig. 1 C and not depicted).
###end p 11
###begin p 12
###xml 0 133 0 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Canonical Wnt signaling is active in ECs during brain angiogenesis and becomes progressively down-regulated during vessel maturation.</bold>
Canonical Wnt signaling is active in ECs during brain angiogenesis and becomes progressively down-regulated during vessel maturation. (A) LacZ whole-mount stained (blue) E9.5 BAT-Gal embryos sectioned and counterstained for isolectin B4 (IB4; red). Panel b is a higher magnification of the boxed area in panel a. Arrows point to nuclear LacZ reporter gene staining. (B, a-d) Whole-mount hindbrain staining for LacZ (reflection; red) and IB4 (green) of BAT-Gal embryos (E13.5 and 17.5) analyzed by confocal microscopy. Arrowheads indicate LacZ-positive nuclei. (B, e-h) Staining of brain cryosections from postnatal BAT-Gal pups (P1 and P5) for LacZ (immunofluorescence [IF], red) and IB4 (green). Arrowheads indicate LacZ-positive nuclei. Positive nuclei outside the vascular system indicate active Wnt signaling in the brain parenchyma. (C) Quantification of LacZ-positive nuclei per 100-mum vessel length shows a significant decrease from E15.5 to 17.5 (five fields per hindbrain; three brains; **, P = 0.0003). Error bars represent SEM.
###end p 12
###begin title 13
###xml 59 62 <span type="species:ncbi:9685">cat</span>
Conditional activation or inactivation of endothelial beta-cat in vivo modulates Cldn3 and plamalemma vesicle-associated protein (Plvap) expression and BBB permeability
###end title 13
###begin p 14
###xml 226 246 220 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Kniesel et al., 1996</xref>
###xml 285 292 276 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 344 363 335 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Brault et al., 2001</xref>
###xml 365 385 356 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Claxton et al., 2008</xref>
###xml 598 619 589 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Srinivas et al., 2001</xref>
###xml 726 733 714 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 947 948 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1085 1096 1058 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, a</xref>
###xml 1105 1106 1078 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1241 1252 1214 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, d</xref>
###xml 1331 1342 1304 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, g</xref>
###xml 1418 1429 1388 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, j</xref>
###xml 1539 1547 1509 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 1776 1784 1743 1751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1914 1915 1881 1882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1964 1965 1931 1932 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2376 2377 2328 2329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2510 2532 2459 2481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Cattelino et al., 2003</xref>
###xml 31 34 <span type="species:ncbi:9685">cat</span>
###xml 98 101 <span type="species:ncbi:9685">cat</span>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 779 782 <span type="species:ncbi:9685">cat</span>
###xml 1397 1400 <span type="species:ncbi:9685">cat</span>
###xml 1738 1741 <span type="species:ncbi:9685">cat</span>
###xml 2092 2095 <span type="species:ncbi:9685">cat</span>
###xml 2467 2470 <span type="species:ncbi:9685">cat</span>
To understand the role of beta-cat in BBB maturation and maintenance, we selectively deleted beta-cat in ECs (loss of function [LOF]) at postnatal day (P) 4, P7, and P14, corresponding to stages of progressive BBB maturation (Kniesel et al., 1996). For this purpose, we crossed betacatlox/lox mice with tamoxifen-inducible Pdgfb-iCreERT2 mice (Brault et al., 2001; Claxton et al., 2008). Cre expression was monitored by EGFP expression (the Pdgfb-iCreERT2 allele includes an internal ribosome entry-EGFP sequence), and recombination was tracked by crossbreeding with ROSA26R∷YFP Cre reporter mice (Srinivas et al., 2001; unpublished data). After induction of Cre-mediated recombination by 4-hydroxy-tamoxifen (4OHT) in betacatlox/lox/Pdgfb-iCreERT2 mice, immunolabeling for beta-cat demonstrated complete absence of the protein in nearly all brain vessels at P4 (Fig. S1, available at ) and P7 and in approximately50% at P14 (not depicted). In Cre- brains, Cldn3 was expressed at low levels in brain vessels at P4 and P7 (Fig. S1) and was consistently expressed in all vessels at P14 (Fig. 2 A, a). In Cre+ littermates, Cldn3 was strongly reduced in most brain vessels at P4 and P7 (Fig. S1) and in approximately half of the vessels at P14 (Fig. 2 A, d). Conversely, Pvlap was poorly expressed in brain vessels of control animals (Fig. 2 A, g; and Fig. S1) but was strongly up-regulated when beta-cat was inactivated (Fig. 2 A, j; and Fig. S1). Quantitative RT-PCR analysis of total brain RNA confirmed strong up-regulation of Plvap mRNA (Fig. 2 C). To functionally test barrier properties, we injected Evans blue i.p. 18 h before tissue harvesting. At P14, extravasated Evans blue was apparent around many vessels after endothelial beta-cat inactivation but not in controls (Fig. 2 B). This effect was even more pronounced at earlier (P4 and P7) postnatal stages (Fig. S1). Cldn5 was consistently expressed in Cre- but was markedly reduced or absent from most Cre+ vessels at P4 and P7 and strongly reduced in approximately50% of the vessels at P14, suggesting that loss of endothelial beta-cat affected the molecular composition of TJs (Fig. S1). Vascular endothelial cadherin (VE-cad) and zonula occludens 1 (ZO-1) were unchanged and localized to all interendothelial junctions (not depicted), whereas plakoglobin (Plako) was slightly increased at adherens junctions of Cre+ samples, confirming previous data showing that Plako can substitute for the loss of beta-cat at adherens junctions in ECs (Fig. S1; Cattelino et al., 2003).
###end p 14
###begin p 15
###xml 0 122 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conditional &#946;-cat GOF or LOF in ECs in vivo modulates Cldn3 and Plvap expression and permeability in brain capillaries.</bold>
###xml 229 230 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 335 336 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 664 665 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 869 870 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1186 1187 1168 1169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1249 1250 1231 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1281 1282 1263 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 17 20 <span type="species:ncbi:9685">cat</span>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 513 516 <span type="species:ncbi:9685">Cat</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 871 875 <span type="species:ncbi:10090">mice</span>
###xml 1130 1134 <span type="species:ncbi:10090">mice</span>
###xml 1188 1192 <span type="species:ncbi:10090">mice</span>
Conditional beta-cat GOF or LOF in ECs in vivo modulates Cldn3 and Plvap expression and permeability in brain capillaries. P14 brain sections of 4OHT-treated LOF mice stained for Cldn3 or Plvap together with IB4. (A, a and g) Cre- control mice. Arrowheads point to Cldn3-positive and Plvap-negative vessels, respectively. (d and j) Cre+ LOF resulted in Cldn3 down- and Plvap up-regulation in approximately50% of brain capillaries. Arrowheads point to Cldn3-negative and Plvap-positive vessels, respectively. beta-Cat GOF in ECs in vivo by 4OHT treatment. E18.5 and P4 brain sections analyzed for Cldn3 or Plvap (green) together with IB4 (red). (b, c, h, and i) Cre- control mice. Arrowheads point to weak Cldn3-positive vessels at E18.5 and a slightly higher level at P4 or strong Plvap at E18.5 and a slightly weaker level at P4. (e, f, k, and l) Cldn3 increase in Cre+ mice at E18.5 and P4. Plvap was down-regulated. Left panels show merge of IB4 and Cldn3 or Plvap; right panels show Cldn3 or Plvap alone in black and white. Insets show higher magnifications. (B) Evans blue injection i.p. 18 h before tissue harvesting in LOF mice. Arrowheads point to extravasated Evans blue in Cre+ mice at P14. (C) Quantitative RT-PCR for Plvap at P7 in LOF (n = 3; **, P = 0.0001) and GOF (n = 3; *, P = 0.0382). Cldn3 was statistically NS. Control is set to 100% (dashed line). Error bars represent SEM.
###end p 15
###begin p 16
###xml 110 121 104 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/wt</sup>
###xml 153 172 147 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Harada et al., 1999</xref>
###xml 174 194 168 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Claxton et al., 2008</xref>
###xml 217 218 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 396 420 390 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, b, c, h, and i</xref>
###xml 509 526 500 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, e and f</xref>
###xml 549 566 540 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, k and l</xref>
###xml 647 648 638 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 658 666 649 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 1258 1259 1246 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 29 32 <span type="species:ncbi:9685">cat</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 441 444 <span type="species:ncbi:9685">cat</span>
###xml 1055 1058 <span type="species:ncbi:9685">cat</span>
###xml 1348 1351 <span type="species:ncbi:9685">cat</span>
###xml 1448 1451 <span type="species:ncbi:9685">cat</span>
To selectively activate beta-cat transcriptional activity in ECs (gain of function [GOF]), we crossed beta-catlox(ex3)/wt mice with Pdgfb-iCreERT2 mice (Harada et al., 1999; Claxton et al., 2008). At E18.5 and P4, Cre- mice showed only faint Cldn3 staining in brain vessels, whereas Plvap was strongly expressed, confirming the immaturity of the BBB at late embryonic and early postnatal stages (Fig. 2 A, b, c, h, and i). Cre-mediated beta-cat activation increased Cldn3 junctional staining at E18.5 and P4 (Fig. 2 A, e and f) and decreased Plvap (Fig. 2 A, k and l). Quantitative RT-PCR confirmed significant down-regulation of Plvap mRNA in Cre+ samples (Fig. 2 C). The Cldn3 mRNA level appeared to be increased, although statistical analysis failed to show significant regulation. The low abundance of this gene in total brain RNA samples is a likely cause for the observed variability and isolation of ECs before RNA extraction may be required to achieve adequate sensitivity in vivo. Nevertheless, even at earlier stages (E13.5), activation of beta-cat transcription resulted in detectably stronger junctional Cldn3 staining and reduction of Plvap in brain vessels (Fig. S2, available at ). Cldn5 expression and localization was not changed between Cre+ and control vessels (Fig. S2). Together, these results illustrate that endothelial beta-cat is required for BBB maturation and function in vivo and that transcriptional activation of beta-cat accelerates BBB maturation.
###end p 16
###begin title 17
###xml 31 34 <span type="species:ncbi:9685">cat</span>
Activation of endothelial beta-cat signaling induces barrier characteristics in vitro
###end title 17
###begin p 18
###xml 353 374 350 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Liebner et al., 2000b</xref>
###xml 516 536 510 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Willert et al., 2003</xref>
###xml 591 608 582 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">Chen et al., 2003</xref>
###xml 45 48 <span type="species:ncbi:9685">cat</span>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 511 514 <span type="species:ncbi:9685">cat</span>
###xml 579 582 <span type="species:ncbi:9685">cat</span>
We next asked whether activation of Wnt/beta-cat signaling could reconstitute BBB characteristics in cultured mouse brain microvascular ECs (MBEs). Because it is essentially impossible to culture MBEs from embryos or pups, we developed an in vitro assay using MBEs from young adult mice, which are known to rapidly loose BBB characteristics in culture (Liebner et al., 2000b). Passaged MBEs were cultured for 6 d in either control or conditioned medium (CM) of L cells, producing Wnt3a, which acts through beta-cat (Willert et al., 2003), or Wnt5a, which does not stabilize beta-cat in ECs (Chen et al., 2003).
###end p 18
###begin p 19
###xml 115 132 115 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A, a and e</xref>
###xml 225 242 225 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A, b and f</xref>
###xml 471 488 471 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A, d and h</xref>
###xml 690 703 687 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A, i&#8211;l</xref>
###xml 876 891 873 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B and C</xref>
###xml 1027 1061 1021 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A, [c, g, and k], B, and C</xref>
###xml 1349 1355 1337 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 626 629 <span type="species:ncbi:9685">cat</span>
###xml 969 972 <span type="species:ncbi:9685">cat</span>
###xml 1120 1123 <span type="species:ncbi:9685">cat</span>
###xml 1257 1260 <span type="species:ncbi:9685">cat</span>
Treatment of MBEs with Wnt3aCM resulted in markedly stronger junctional staining of Cldn3 compared with controlCM (Fig. 3 A, a and e). The localization and staining intensity of Cldn5, ZO-1, Plako, and VE-cad was unaffected (Fig. 3 A, b and f; and not depicted). Freeze-fracture analysis revealed more TJ strands in Wnt3aCM-treated cells, regularly showing areas of high protoplasmic fracture face (P-face) association of TJ particles, resembling TJs of BBB ECs in vivo (Fig. 3 A, d and h). As a control, we activated MBEs with Wnt5aCM, which closely corresponds to control conditions concerning Cldn3, Cldn5, and active beta-cat staining as well as TJ particle distribution on the P-face (Fig. 3 A, i-l). Quantitative RT-PCR and Western blotting confirmed the up-regulation of Cldn3 in Wnt3aCM but not in Wnt5aCM-stimulated cells on the mRNA and protein level, respectively (Fig. 3, B and C). As expected, nuclear immunolabeling and Western blotting of activated beta-cat and induction of the canonical Wnt target gene Axin2 (Fig. 3, A, [c, g, and k], B, and C) were strongest in Wnt3aCM-treated cells, confirming beta-cat stabilization by Wnt3aCM. None of these parameters were induced by Wnt5aCM. Other junctional proteins, including Cldn5, VE-cad, beta-cat, Plako, ZO-1, Ocln, Cldn1, and Cldn12 were not modified in distribution and expression (Fig. 3 and not depicted).
###end p 19
###begin p 20
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Wnt3aCM but not Wnt5aCM induced TJs and barrier properties in MBEs.</bold>
###xml 567 568 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 597 598 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 631 632 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 318 321 <span type="species:ncbi:9685">cat</span>
###xml 884 887 <span type="species:ncbi:9685">cat</span>
Wnt3aCM but not Wnt5aCM induced TJs and barrier properties in MBEs. Wild-type MBEs treated with controlCM, Wnt3aCM, or Wnt5aCM in vitro. (A, a, e, and i) IHC staining for Cldn3. (b, f, and j) IHC staining for Cldn5. Panels are the same magnification as indicated in panel k. (c, g, and k) IHC staining for active beta-cat (clone 8E7). Arrowheads point to positive nuclei. (d, h, and l) Freeze-fracture EM. Arrowheads point to P-face-associated TJ ridges. (B) mRNA levels for Cldn1, Cldn3, Cldn5, Cldn12, Ocln, Plvap, and Axin2 measured by quantitative RT-PCR. Cldn3 (n = 3; *, P = 0.0319), Plvap (n = 3; *, P = 0.0098), and Axin2 (n = 3; **, P = 0.005); other tested genes were not significantly altered. Control is set to 100% (dashed line). (C) Western blotting for Cldn3 and Cldn5. alpha-Tubulin/tubulin alpha1A served as a loading control. Western blotting for 8E7 and total beta-cat. No band could be detected in Wnt5aCM-treated cells. See graphs for densiomeric quantification of bands. Error bars represent SEM. Data are representative of at least three independent experiments.
###end p 20
###begin p 21
###xml 161 168 152 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 181 198 169 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 219 238 207 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Harada et al., 1999</xref>
###xml 240 259 228 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Brault et al., 2001</xref>
###xml 438 456 423 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Wadia et al., 2004</xref>
###xml 467 474 449 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 570 599 552 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, A [a and b], B, and C</xref>
###xml 647 672 626 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, A [c and h] and C</xref>
###xml 38 41 <span type="species:ncbi:9685">cat</span>
###xml 104 107 <span type="species:ncbi:9685">cat</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 412 415 <span type="species:ncbi:9685">cat</span>
###xml 642 645 <span type="species:ncbi:9685">cat</span>
To directly validate the role of beta-cat in Cldn expression, we genetically deleted or stabilized beta-cat in ECs in vitro by harvesting brain ECs from beta-catlox/lox and beta-catlox(ex3)/lox(ex3) mice, respectively (Harada et al., 1999; Brault et al., 2001). Cells were treated with cell-permeable transactivating regulatory protein (TAT)-Cre to achieve loxP site-mediated recombination, thus generating beta-cat LOF and GOF in vitro (Wadia et al., 2004). beta-catlox/lox cells grew and behaved as wild-type cells, showing Cldn3 up-regulation upon Wnt3aCM treatment (Fig. 4, A [a and b], B, and C), an effect abrogated by the loss of beta-cat (Fig. 4, A [c and h] and C).
###end p 21
###begin p 22
###xml 0 38 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-Cat LOF and GOF in MBEs in vitro.</bold>
###xml 47 54 41 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 67 84 58 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 197 204 182 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 327 328 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 378 379 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 414 431 393 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 579 580 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 616 623 586 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 625 626 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 658 659 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 689 706 656 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 708 709 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 843 844 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 880 887 844 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 889 890 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 922 923 886 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 953 970 914 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 972 973 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1115 1122 1073 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 1135 1152 1090 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 1323 1340 1269 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 1344 1345 1290 1291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 5 8 <span type="species:ncbi:9685">Cat</span>
###xml 141 144 <span type="species:ncbi:9685">cat</span>
###xml 368 371 <span type="species:ncbi:9685">cat</span>
###xml 496 499 <span type="species:ncbi:9685">cat</span>
###xml 534 537 <span type="species:ncbi:9685">cat</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 995 999 <span type="species:ncbi:10090">mice</span>
###xml 1230 1233 <span type="species:ncbi:9685">cat</span>
###xml 1264 1267 <span type="species:ncbi:9685">cat</span>
beta-Cat LOF and GOF in MBEs in vitro. beta-Catlox/lox and beta-catlox(ex3)/lox(ex3) MBEs were treated with TAT-Cre in vitro to achieve beta-cat LOF and GOF, respectively. (A, a-c and f-h) beta-Catlox/lox with or without TAT-Cre, stimulated with controlCM (CCM) or Wnt3aCM. IF staining reveals increased junctional Cldn3 in Cre-/Wnt3aCM and a complete absence of beta-cat in Cre+/Wnt3aCM. (d, e, i, and j) beta-Catlox(ex3)/lox(ex3) MBEs with or without TAT-Cre, and IF stained for Cldn3 and beta-cat. Arrowheads point to nuclear beta-cat. (B) Quantitative RT-PCR for Cldn3 in Cre-/Wnt3aCM-treated cells from beta-catlox/lox (n = 3; **, P = 0.0048) and in Cre+/controlCM cells from beta-catlox(ex3)/lox(ex3) (n = 3; *, P = 0.0341) mice. Other tested genes were not significantly altered. Axin2 induction confirmed canonical Wnt signaling in Cre-/Wnt3aCM-treated cells from beta-catlox/lox (n = 3; **, P = 0.0006) and in Cre+/controlCM cells from beta-catlox(ex3)/lox(ex3) (n = 3; **, P = 0.0029) mice. Controls are set as 100% (dashed lines). Error bars represent SEM. (C) Western blot analysis for Cldn3 in beta-catlox/lox and beta-catlox(ex3)/lox(ex3) cells. Transcription and translation of an N-terminal truncated form of beta-cat are detected by the anti-beta-cat antibody and represented by the bottom band in beta-catlox(ex3)/lox(ex3)/Cre+ cells. See graphs for densiomeric quantification of Western blot bands. Data are representative of at least three independent experiments.
###end p 22
###begin p 23
###xml 110 146 107 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, A [d, e, i, and j], B, and C</xref>
###xml 186 187 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 196 213 187 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 494 517 482 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">Lampugnani et al., 2002</xref>
###xml 18 21 <span type="species:ncbi:9685">cat</span>
###xml 172 175 <span type="species:ncbi:9685">cat</span>
###xml 351 354 <span type="species:ncbi:9685">cat</span>
###xml 584 587 <span type="species:ncbi:9685">cat</span>
###xml 736 739 <span type="species:ncbi:9685">cat</span>
In contrast, beta-cat stabilization led to an increase in Cldn3 junctional staining, mRNA, and protein level (Fig. 4, A [d, e, i, and j], B, and C). A double band for beta-cat in the Cre+/beta-catlox(ex3)/lox(ex3) cell extract demonstrates the effective, although not complete, recombination of exon3 by the Cre recombinase. Thus, the effects of beta-cat stabilization are comparable with those of stimulating the cells with Wnt3aCM. When we infected a nonbrain-derived endothelioma cell line (Lampugnani et al., 2002) exhibiting low barrier properties with N-terminal truncated beta-cat, we observed a significant increase in Cldn3 and barrier properties (freeze-fracture analysis and decrease in Pvlap), suggesting that elevated beta-cat transcriptional activity may induce BBB properties also in nonbrain-derived ECs (Fig. S3, available at ).
###end p 23
###begin title 24
###xml 92 95 <span type="species:ncbi:9685">cat</span>
Cldn3 up-regulation requires transcriptionally active rather than junctional localized beta-cat in MBEs in vitro
###end title 24
###begin p 25
###xml 195 218 192 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">Quasnichka et al., 2006</xref>
###xml 459 481 443 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Vleminckx et al., 1999</xref>
###xml 655 680 639 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A [a&#8211;c] and B [a]</xref>
###xml 84 87 <span type="species:ncbi:9685">cat</span>
###xml 294 297 <span type="species:ncbi:9685">cat</span>
###xml 418 421 <span type="species:ncbi:9685">cat</span>
To better discriminate the effects of junctional versus transcriptional active beta-cat on Cldn3 regulation, we infected MBEs with an adenoviral vector containing dominant-negative TCF4 (dnTCF4; Quasnichka et al., 2006), which inhibits signaling but does not affect the junctional pool of beta-cat. Alternatively, MBEs were infected with a lentiviral vector containing LefDeltaN-betaCTA, which dominantly induces beta-cat signaling without binding to VE-cad (Vleminckx et al., 1999). Adenoviral infection with dnTCF4 completely abrogated the Wnt3aCM-mediated up-regulation of Cldn3 and Axin2 in primary MBEs, whereas Plvap was significantly up-regulated (Fig. 5, A [a-c] and B [a]).
###end p 25
###begin p 26
###xml 0 103 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cldn3 up-regulation requires transcriptionally active rather than junctional &#946;-cat in MBEs in vitro.</bold>
###xml 356 357 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 387 388 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 420 421 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 470 471 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 687 688 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 717 718 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 751 752 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 82 85 <span type="species:ncbi:9685">cat</span>
Cldn3 up-regulation requires transcriptionally active rather than junctional beta-cat in MBEs in vitro. (A, a-c; and B, a) MBEs were either treated with Wnt3aCM or control CM and infected with dnTCF4 adenovirus or a control. (A, a-c) IF stainings for Cldn3. dnTCF4 abrogated the effect of Wnt3aCM on junctional Cldn3. (B, a) Quantitative RT-PCR for Cldn3 (n = 3; **, P = 0.0095), Plvap (n = 3; *, P = 0.035), and Axin2 (n = 3; **, P = 0.004) with Wnt3aCM and for Plvap (n = 3; **, P = 0.002) with Wnt3aCM and dnTCF4. (A, d; and B, b) MBEs infected with LefDeltaN-betaCTA lentivirus or a control. Junctional localization of Cldn3 increased in IF stainings. Quantitative RT-PCR for Cldn3 (n = 3; **, P = 0.002), Plvap (n = 3; **, P = 0.008), and Axin2 (n = 3; **, P < 0.0001). Controls are set as 100% (dashed lines). Green nuclei show an anti-V5-TAG (c) and an anti-HA-TAG (d) staining of dnTCF4 and LefDeltaN-betaCTA, respectively, confirming infection of the target cells. Error bars represent SEM.
###end p 26
###begin p 27
###xml 197 220 190 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A [d] and B [b]</xref>
###xml 294 297 <span type="species:ncbi:9685">cat</span>
Lentiviral infection of the dominant-active LefDeltaN-betaCTA construct had principally the same, but a notably stronger, effect than Wnt3aCM, namely Cldn3 up-regulation and Plvap down-regulation (Fig. 5, A [d] and B [b]). Together, these results show that the transcriptional activity of beta-cat is necessary and sufficient to up-regulate Cldn3 and down-regulate Plvap, leading to increased barrier properties of brain ECs.
###end p 27
###begin p 28
###xml 263 281 257 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Nitta et al., 2003</xref>
###xml 334 354 328 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">Wolburg et al., 2003</xref>
###xml 817 836 802 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Taddei et al., 2008</xref>
###xml 50 53 <span type="species:ncbi:9685">cat</span>
###xml 126 129 <span type="species:ncbi:9685">cat</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 512 515 <span type="species:ncbi:9685">cat</span>
###xml 645 648 <span type="species:ncbi:9685">cat</span>
###xml 729 732 <span type="species:ncbi:9685">cat</span>
###xml 873 876 <span type="species:ncbi:9685">cat</span>
###xml 1109 1112 <span type="species:ncbi:9685">cat</span>
###xml 1269 1272 <span type="species:ncbi:9685">cat</span>
Cldn3 is an important downstream effector of beta-cat signaling, whereas Cldn5, although affected in vivo by the loss of beta-cat, appears to be ubiquitous and more stably expressed. Although newborn Cldn5-null mice die immediately after birth for defective BBB (Nitta et al., 2003), data reported in this study and in previous work (Wolburg et al., 2003) strongly suggest that Cldn3 is a major determinant of BBB, cooperating with Cldn5 in maintaining low permeability. The precise mechanism through which beta-cat regulates the expression of Cldn3 is yet to be defined, but the promoter contains consensus-binding domains for the TCF-Lef-beta-cat transcriptional complex (unpublished data). Recently, we demonstrated that beta-cat can stabilize FoxO-1 binding to the Cldn5 promoter, contributing to its repression (Taddei et al., 2008). In this study, we found that beta-cat in vivo is required to maintain high levels of Cldn5 expression in brain microvasculature. Although we do not know the exact mechanism of this regulation in brain microvasculature, it is likely that the transcriptional role of beta-cat varies depending on the specialized region of the vascular tree. Other BBB-related Cldns, such as Cldn1 and Cldn12, were not significantly modified by beta-cat signaling.
###end p 28
###begin p 29
###xml 342 358 336 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Lim et al., 2008</xref>
###xml 932 953 920 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">Hallmann et al., 1995</xref>
###xml 1088 1107 1076 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Sparks et al., 2000</xref>
###xml 1109 1135 1097 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Carson-Walter et al., 2005</xref>
###xml 205 208 <span type="species:ncbi:9685">cat</span>
###xml 327 330 <span type="species:ncbi:10116">rat</span>
###xml 694 697 <span type="species:ncbi:9685">cat</span>
###xml 784 787 <span type="species:ncbi:9685">cat</span>
In this study, we mostly focus on the role of canonical Wnt signaling on vascular junction organization and permeability control. However, other barrier-associated genes may also be controlled by Wnt/beta-cat. Recently, the transporters p-glycoprotein and MDR-1 were shown to be up-regulated by specific GSK3beta inhibitors in rat brain ECs (Lim et al., 2008). Our own preliminary results did not confirm a regulation of p-glycoprotein and MDR-1 but indicate that Abcg2 and the glucose transporter Slc2a1 were notably up-regulated in MBEs by Wnt3aCM (unpublished data). Although further studies need to elucidate the entire set of BBB-related genes directly or indirectly regulated by Wnt/beta-cat, these findings fit well with the concomitant down-regulation of Plvap by active beta-cat in vitro and in vivo. Plvap is associated with vessels with high vesicular transport and negatively correlates with the development of the BBB (Hallmann et al., 1995). Conversely, BBB microvessels up-regulate Plvap under pathological conditions such as Alzheimer's disease, brain tumors, and stroke (Sparks et al., 2000; Carson-Walter et al., 2005).
###end p 29
###begin p 30
In conclusion, we provide first and direct evidence for the role of the canonical Wnt pathway as a key regulator of the BBB phenotype in ECs. The BBB is indispensable for brain function, and understanding the molecular mechanisms, which determine barrier properties in ECs, will greatly contribute to the development of new therapeutic strategies to modulate the BBB in the treatment for stroke, multiple sclerosis, and brain tumors.
###end p 30
###begin title 31
Materials and methods
###end title 31
###begin title 32
Animals
###end title 32
###begin p 33
###xml 58 75 55 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox(ex3)/lox(ex3)</sup>
###xml 77 96 74 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Harada et al., 1999</xref>
###xml 107 114 101 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 116 135 110 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Brault et al., 2001</xref>
###xml 152 172 146 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Claxton et al., 2008</xref>
###xml 195 215 189 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Maretto et al., 2003</xref>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
The following transgenic mouse strains were used: beta-catlox(ex3)/lox(ex3) (Harada et al., 1999), beta-catlox/lox (Brault et al., 2001), Pdgfb-iCreER (Claxton et al., 2008), and BAT-Gal/C57Bl6 (Maretto et al., 2003). For MBE preparation, C57Bl6 wild-type mice were used (Charles River Laboratories).
###end p 33
###begin title 34
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Preparation of primary mouse brain ECs
###end title 34
###begin p 35
###xml 76 97 76 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Liebner et al., 2000b</xref>
###xml 99 120 99 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">Calabria et al., 2006</xref>
###xml 368 369 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 253 257 <span type="species:ncbi:9913">calf</span>
Mouse brain microvascular fragments were processed as described previously (Liebner et al., 2000b; Calabria et al., 2006). Capillary fragments were seeded in culture medium (DME, 20% FCS, 100 mug/ml heparin, 5 mug/ml EC growth supplement [homemade from calf brain], 100 U/L penicillin/streptomycin, 2 mM glutamin, 1x MEM, and 1 mM Na-pyruvate) at a density of 1.5 x 104 cells/ml on collagen I-coated wells. ECs were selected for puromycin (4 mug/ml) resistance for 2 d, grown to confluency and passaged 1:2, and grown for an additional 6 d in the presence of control, Wnt3a, or Wnt5aCM. Cells were fixed with methanol for immunofluorescent staining or lysed for RNA and protein, respectively.
###end p 35
###begin title 36
Viral preparations
###end title 36
###begin p 37
###xml 287 309 270 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Vleminckx et al., 1999</xref>
###xml 511 528 494 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Dull et al., 1998</xref>
###xml 625 648 608 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">Quasnichka et al., 2006</xref>
###xml 100 103 <span type="species:ncbi:9685">cat</span>
The lentiviral construct LefDeltaN-betaCTA lacking the armadillo repeats with constitutive TCF-beta-cat transcriptional activity was used. The day after splitting, MBEs were infected with lenti-GFP or lenti-LefDeltaN-betaCTA (provided by K. Vleminckx, University of Gent, Gent, Belgium; Vleminckx et al., 1999) and fixed or extracted after 1 wk. Lentiviral and packaging plasmids were provided by L. Naldini (San Raffaele Telethon Institute for Gene Therapy, Milan, Italy) and produced as described previously (Dull et al., 1998). Adenoviral dnTCF4 was provided by S.J. George (Bristol Heart Institute, Bristol, England, UK; Quasnichka et al., 2006). The day after splitting, one set of cells was treated with Wnt3aCM, and when they reached confluency, they were infected with Ad-GFP or Ad-dnTCF4. 72 h later, the infection cells were fixed or extracted for quantitative RT-PCR.
###end p 37
###begin title 38
###xml 40 43 <span type="species:ncbi:9685">cat</span>
Conditional deletion/activation of beta-cat in vivo and in vitro
###end title 38
###begin p 39
###xml 116 134 114 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Wadia et al., 2004</xref>
ECs were treated with 50 mug/ml TAT-Cre for 60 min in DME without serum followed by 100 muM chloroquine for 30 min (Wadia et al., 2004). The cells were washed with DME and cultured with complete medium with or without WntCM.
###end p 39
###begin p 40
###xml 47 67 44 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Claxton et al., 2008</xref>
###xml 142 149 133 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 151 170 142 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Brault et al., 2001</xref>
###xml 208 215 196 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lox/lox</sup>
###xml 9 12 <span type="species:ncbi:9685">cat</span>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 129 132 <span type="species:ncbi:9685">cat</span>
###xml 373 379 <span type="species:ncbi:3818">peanut</span>
For beta-cat deletion, in vivo Pdgfb-iCreERT2 (Claxton et al., 2008) lines were crossed to mice harboring floxed alleles of beta-cat (beta-catlox/lox; Brault et al., 2001) to obtain homozygous floxed beta-catlox/lox pups, of which 50% also carried one Pdgfb-iCreERT2 allele. 4OHT (Sigma-Aldrich) was dissolved in absolute ethanol at 20 mg/ml, diluted to 4 mg/ml in sterile peanut oil, and injected i.p. at 20 mul/g into pups 3 d before tissue harvesting. When harvesting embryonic tissues at E13.5, the mothers were injected with 1 mg 4OHT at E11.5 and 12.5. For control experiments on promoter activity and recombination frequency, see Online supplemental material.
###end p 40
###begin title 41
Evans blue permeability
###end title 41
###begin p 42
###xml 547 565 533 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Hamer et al., 2002</xref>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
A 1% sterile solution of Evans blue (Sigma-Aldrich) in PBSa was injected i.p. 18-24 h before the animals were harvested. To remove the Evans blue from the vasculature, the mice were perfused with PBSa while under terminal anesthesia. Frozen 12-mum sections of brain and 15-mum sections of skin were dried onto slides for approximately 10 min at 37degreesC (provided by G. Elia, Cancer Research Institute, London, England, UK). They were fixed in 4degreesC acetone for 2 min, air dried, dipped in xylene, and mounted in dibutyl polystyrene xylene (Hamer et al., 2002).
###end p 42
###begin title 43
Antibodies
###end title 43
###begin p 44
###xml 227 246 217 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">Vecchi et al., 1994</xref>
###xml 311 334 301 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">Lampugnani et al., 2002</xref>
###xml 445 466 435 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">Hallmann et al., 1995</xref>
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
###xml 94 97 <span type="species:ncbi:9685">cat</span>
###xml 136 139 <span type="species:ncbi:9685">cat</span>
###xml 158 161 <span type="species:ncbi:10116">Rat</span>
###xml 249 252 <span type="species:ncbi:10116">Rat</span>
###xml 337 340 <span type="species:ncbi:10116">Rat</span>
The following mouse mAbs were used: anti-alpha-tubulin and anti-Cldn5 (Invitrogen), anti-beta-cat (BD Biosciences), and antiactive beta-cat (8E7; Millipore). Rat anti-PECAM/CD31 clone MEC13.3 mAb has been described previously (Vecchi et al., 1994). Rat anti-VE-cad clone BV13 mAb has been described previously (Lampugnani et al., 2002). Rat monoclonal anti-MECA-32/Plvap mAb was provided by R. Hallmann (University of Munster, Munster, Germany; Hallmann et al., 1995).
###end p 44
###begin p 45
###xml 47 51 <span type="species:ncbi:9925">goat</span>
###xml 85 91 <span type="species:ncbi:9986">rabbit</span>
###xml 107 113 <span type="species:ncbi:9986">rabbit</span>
###xml 138 144 <span type="species:ncbi:9986">rabbit</span>
The following polyclonal antibodies were used: goat anti-beta-galactosidase (Abcam), rabbit anti-Cldn3 and rabbit anti-ZO-1 (Invitrogen), rabbit anti-collagen IV (AbD Serotec), biotinylated isolectin B4 (Sigma-Aldrich), and Alexa Fluor direct-conjugated isolectin 568 and 488 (Invitrogen).
###end p 45
###begin p 46
###xml 179 184 <span type="species:ncbi:10090">mouse</span>
###xml 243 248 <span type="species:ncbi:10090">mouse</span>
The following secondary antibodies were used: appropriated antibodies and streptavidin conjugates Alexa Fluor 350, 488, 555, 568, and 633 were purchased from Invitrogen (the anti-mouse antibodies were highly cross-absorbed against nonspecific mouse proteins). For nuclear stain on brain sections, Hoechst 333258 was diluted to 1 mug/ml in PBS/0.2% Tween 20 and incubated at RT for 5 min. Alternatively, TOTO-3 (1:1,000; Invitrogen) was used.
###end p 46
###begin title 47
Immunohistochemistry (IHC)
###end title 47
###begin p 48
###xml 86 106 83 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">Liebner et al., 2004</xref>
###xml 755 776 737 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Gerhardt et al., 2003</xref>
###xml 712 715 <span type="species:ncbi:9685">cat</span>
beta-Galactosidase staining of BAT-Gal embryos was performed as previously described (Liebner et al., 2004). Hindbrains were dissected out from PFA-fixed embryos, washed in PBS, and subjected to isolectin. LacZ was either detected as reflection of the 488-nm laser or by antibody staining as indicated. Eyes were fixed in PFA for 5 min on ice, and retinas were subsequently dissected in cold PBSa. Retinas were fixed in 4degreesC methanol and stored at -20degreesC. Before staining, the retinas were placed in PBSa to rehydrate. Retinas were incubated in blocking buffer (1% BSA + 0.5% Triton X-100 in PBSa) for 1 h. Immunofluorescent staining with anti-collagen IV, Cldn5, MECA-32/Plvap, VE-cad, ZO-1, and beta-cat was performed as previously described (Gerhardt et al., 2003). Appropriate Alexa Fluor-conjugated secondary antibodies were used for detection.
###end p 48
###begin p 49
###xml 176 197 175 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">Liebner et al., 2000a</xref>
Brains were isolated, placed in Tissue Tek (Sakura Finetek), and slowly frozen in liquid nitrogen vapor. 10-12-mum cryosections were fixed and stained as described previously (Liebner et al., 2000a).
###end p 49
###begin p 50
Flat mounted hindbrains were analyzed by fluorescence microscopy using a microscope (80i; Nikon;) with a 20x NA 0.75 or 40x NA 1.4 oil/RT objective equipped with a digital camera (DS-5Mc; Nikon). Measurements were performed by using NIS Elements software (version 3.0; Nikon). Alternatively, images were captured by confocal laser-scanning microscopy using a C1si microscope (Nikon) with a 40x NA 1.4 oil/RT objective or an LCS NT microscope (Leica). Retinas and brain sections were analyzed at RT by confocal laser-scanning microscopy using an upright microscope (LSM 510; Carl Zeiss, Inc.) with 405-, 488-, 543-, and 633-nm laser lines. The lenses used were C Apochromat 10x NA 0.45w, Plan-Neofluar 25x NA 0.80w, and C Apochromat 40x NA 1.2w. Digital zoom factor two or three was used for detail panels. Images and stacks were processed using ImageJ (National Institutes of Health) and Photoshop (CS; Adobe).
###end p 50
###begin title 51
RNA preparation and quantitative RT-PCR
###end title 51
###begin p 52
Total RNA from cultured cells was prepared with the RNeasy Mini kit (QIAGEN) according to the manufacturer's protocol. RNA was reverse transcribed with the Transcriptor First Strand cDNA Sythesis kit (Roche) using 1 mug of total RNA per 20-mul reaction. For real-time PCR reactions, Absolute Quantitative RT-PCR SYBR Green Fluorescein Mix (Thermo Fisher Scientific) was used as described in the protocol on a DNA Engine Opticon 2 (Bio-Rad Laboratories).
###end p 52
###begin p 53
The following primers were used for identification: Cldn1 (sense 5'-GATGTGGATGGCTGTCATTGG-3', antisense 5'-ACACCTCCCAGAAGGCAGAGG-3'), Cldn3 (sense 5'-CGTACAAGACGAGACGGCCAAG-3', antisense 5'-CACGTACAACCCAGCTCCCATC-3'), Cldn5 (sense 5'-ATGTCGTGCGTGGTGCAGAGT-3', antisense 5'-GCGCCGGTCAAGGTAACAAAG-3'), Cldn12 (sense 5'-CAGACAGGCTGCTTGGAGAAAC-3', antisense 5'-AGGCAATACCACACAGGAAGGA-3'), Ocln (sense 5'-GTGAATGGCAAGCGATCATACC-3', antisense 5'-TGCCTGAAGTCATCCACACTCA-3'), Plvap (sense 5'-GACTACGCGACGTGAGATGGA-3', antisense 5'-AGGATGATAGCGGCGATGAAG-3'), and Axin2 (sense 5'-GCCGACCTCAAGTGCAAACTC-3', antisense 5'-GGCTGGTGCAAAGACATAGCC-3') and, as reference for the house keeping genes, RNA polymerase II (sense 5'-ATGAGCTGGAACGGGAATTTGA-3', antisense 5'-ACCACTTTGATGGGATGCAGGT-3') and glucose-6-phosphate dehydrogenase (sense 5'-GGACGACATCCGAAAGCAGAGT-3', antisense 5'-GAATAGACGGTTGGCCTGCATC-3'). Quantitative RT-PCR conditions were 15 min at 95degreesC, 40 cycles of 15 s at 94degreesC, 30 s at 60degreesC, and 30 s at 72degreesC. For intron less genes, negative RT controls were performed to exclude the possibility of genomic background.
###end p 53
###begin title 54
Western blotting
###end title 54
###begin p 55
Western blot analysis was performed according to standard protocols. In brief, confluent cells were washed with ice-cold PBS and scraped in lysis buffer (50 mM Tris and 150 mM NaCl, pH 7.4, containing 1% Triton X-100, 1% Nonidet P-40, 0.5% sodium-deoxycholate, 0.1% sodium-dodecyl-sulfate, 1 mM phenylmethylsulfonyl fluoride, 15 mug/ml leupeptin, 71 mug/ml phenanthrolyne, and 20 U/ml aprotine [Sigma-Aldrich]). The insoluble material was removed by centrifugation at 12,000 rpm for 10 min. Alternatively, cultured cells were lysated by boiling in a modified laemli sample buffer (2% SDS, 20% glycerol, and 125 mM Tris-HCl, pH 6.8). The protein content was measured according to the bicinchoninic acid method (Thermo Fisher Scientific). Total cell lysates were separated by SDS-PAGE under reducing conditions, transfered to a nitrocellulose membrane, and analyzed by immunoblotting with specific antibodies.
###end p 55
###begin title 56
Freeze fracturing
###end title 56
###begin p 57
###xml 85 106 85 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Liebner et al., 2000b</xref>
Freeze fracturing on glutaraldehyde-fixed ECs was performed as previously described (Liebner et al., 2000b). Negatives were digitized, and images were arranged in Photoshop.
###end p 57
###begin title 58
Statistical analysis
###end title 58
###begin p 59
###xml 62 63 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Results are presented as mean +/- SEM. A two-tailed Student's t test was used to analyze the difference between two groups. Values were regarded as significant at P < 0.05.
###end p 59
###begin title 60
Online supplemental material
###end title 60
###begin p 61
###xml 52 55 <span type="species:ncbi:9685">cat</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 222 225 <span type="species:ncbi:9685">cat</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 346 349 <span type="species:ncbi:9685">cat</span>
Fig. S1 shows that conditional inactivation of beta-cat in ECs of postnatal mice led to down-regulation of Cldn3 and Cldn5 and increased permeability in brain capillaries. Fig. S2 shows that conditional activation of beta-cat transcriptional activity induced Cldn3 only in brain vessels of early postnatal mice. Fig. S3 shows that activated beta-cat can induce Cldn3 and TJ formation in a nonbrain-derived endothelioma cell line. Online supplemental material is available at .
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
[Supplemental Material Index]
###end title 63
###begin p 64
The MECA-32/Plvap antibody was provided by R. Hallmann. We thank S. Thom, A. Siepmann, and R. Knittel for excellent technical support. Many thanks to G. Elia (London Research Institute, London, England, UK) for frozen sections and advice on IHC and to L. Davinson for proofreading. We are grateful to S. Watling, C. Thrussell, and C. Darnborough for excellent animal husbandry and assistance with tamoxifen and Evans blue injections as well as tissue harvesting.
###end p 64
###begin p 65
This study was supported by the Deutsche Forschungs Gemeinschaft (research group 501 vascular homeostasis, PL 158/7-3 to S. Liebner and K.H. Plate and ME 820/3-6 to H. von Melchner), the Excellence Cluster Cardio-Pulmonary System (S. Liebner and K.H. Plate), Cancer Research UK (J. Babbage and H. Gerhardt), EMBO Young Investigator Program (H. Gerhardt), Associazione Italiana per la Ricerca sul Cancro, Association for International Cancer Research, the European Community (integrated project contract number LSHG-CT-2004-503573; NoE MAIN 502935; NoE EVGN 503254; EUSTROKE integrated project), Istituto Superiore di Sanita, Italian Ministry of Health, the Ministry of University and Research (fund for the cofinancing of research activities of University protocol 2006058482_002), and Fondation Leducq Transatlantic Network of Excellence (E. Dejana).
###end p 65

